Technology | November 20, 2013

Gallium-68 DOTATOC Receives FDA Orphan Drug Designation for NET Management

Radiopharmaceuticals and tracers nuclear molecular imaging pet systems SNMMI
November 20, 2013 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) announced that the U.S. Food and Drug Administration (FDA) has designated the radiopharmaceutical Gallium-68 (DOTA0-Phel-Tyr3) octreotide (Ga-68 DOTATOC) as an orphan drug for the management of neuroendocrine tumors (NET). This designation may lead to faster approval of the agent, which would greatly benefit NET patients in the United States. Currently, there are only a few small U.S.-based clinical trials for Ga-68 labeled NET positron emission tomography (PET) agents available for patients, who must otherwise travel out of the country if the scan is required to manage their disease.
 
In August 2013, SNMMI’s Clinical Trials Network (CTN) submitted an application to the FDA for orphan drug designation for Ga-68 DOTATOC under the Orphan Drug Act. This act provides for granting special status to a drug or biological product to treat a rare disease or condition. For a drug to qualify for orphan designation, the disease or condition must affect fewer than 200,000 people. With a prevalence of approximately 110,000 patients in the United States with NETs, Ga-68 DOTATOC meets this requirement.
 
With this new orphan drug designation, Ga-68 DOTATOC will be directed down a unique pathway within the FDA. On its road to approval, fewer patients will likely be required for clinical trials, and funds may be available for studies through the Office of Orphan Products Development (OOPD) grant program to support the clinical development of products where the proposed product will be superior to the existing product (Octreoscan). 
 
“The next step in this process will be to meet with FDA officials to discuss the data needed for regulatory approval, factoring in the extensive literature on the safety and efficacy of this agent and the patients currently enrolled in an ongoing prospective trial,” said Michael Graham, Ph.D., M.D. and co-chair, CTN.
 
SNMMI’s CTN will remain involved in the clinical trials for Ga-68-labeled DOTA agents as new studies begin. CTN has developed a comprehensive repository of materials to aid in the initiation and conduct of clinical trials including release criteria, an imaging manual, data collection forms and a template investigational new drug (IND) application for Ga-68 agents to help increase investigational use.
 
 “I think I speak for all NET patients when I say this is a great first step towards approval of this agent in the United States,” said Josh Mailman, chairman, SNMMI’s Patient Advocacy Advisory Board and president, NorCalCarciNET. “Ga-68-labeled NET PET radiopharmaceuticals will reduce the time it takes to image a NET patient from 2-3 days to just a few hours. It has also been shown in early studies in the U.S. and those overseas to change treatment paths for a number of patients. Lastly, the exposed dose of radiation is lower than the current standard of care. ”
 
For more information: www.snmmi.org

Related Content

PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
Vital Unveils Newest Vitrea Advanced Visualization Release at RSNA 2017
Technology | Advanced Visualization | December 04, 2017
Vital Images unveiled the newest version of Vitrea Advanced Visualization software, the cornerstone of its imaging...
Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease
News | Radiopharmaceuticals and Tracers | October 27, 2017
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a funding partnership to...
Netherlands Cancer Institute Exploring Molecular Imaging Technology for Prostate Cancer Surgery
News | Molecular Imaging | October 26, 2017
The Netherlands Cancer Institute (NKI) announced it has received funding from the Dutch Cancer Society (KWF...
SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Biodex Unveils Atomlab 500 Dose Calibrator and Wipe Test Counter
Technology | Nuclear Imaging | October 19, 2017
Biodex Medical Systems announced the full release of the Atomlab Dose Calibrator and Wipe Test Counter to the market...
ASNC and ASE Team Up to Expand ImageGuide Registry
News | Cardiovascular Ultrasound | October 12, 2017
The American Society of Nuclear Cardiology (ASNC) and the American Society of Echocardiography (ASE) jointly announced...
MR Solutions Showcases Multimodality MRI Solutions on Two Continents
News | Magnetic Resonance Imaging (MRI) | October 11, 2017
October 11, 2017 — MR Solutions took their cryogen-free preclinical multimodality...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
News | Business | September 19, 2017
September 19, 2017 — Invicro LLC, a provider of imaging services and software for research and drug development, anno
Overlay Init